Celldex Therapeutics (CLDX) Total Current Liabilities (2010 - 2026)

Celldex Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $51.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 60.76% year-over-year to $51.5 million; the TTM figure through Mar 2026 stood at $51.5 million (up 60.76% YoY), while the FY2025 annual figure was $51.0 million, up 29.09% from the prior year.
• Total Current Liabilities was $51.5 million for Q1 2026 at Celldex Therapeutics, up from $51.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $51.5 million in Q1 2026 to a low of $14.6 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $29.9 million across 5 years, with a median of $29.9 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 106.72% in 2022, then tumbled 47.76% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $18.6 million in 2022, then soared by 67.25% to $31.1 million in 2023, then increased by 26.91% to $39.5 million in 2024, then increased by 29.09% to $51.0 million in 2025, then advanced by 0.94% to $51.5 million in 2026.
• The last three Total Current Liabilities figures came in at $51.5 million (Q1 2026), $51.0 million (Q4 2025), and $46.5 million (Q3 2025), per Business Quant data.